Advances in Biologic Therapies for Inflammatory Bowel Disease: Efficacy and Safety Profiles

Andreas Migdanis^*
*Correspondence: Andreas Migdanis, Department of Gastroenterology, University Hospital of Larissa, Viopolis Mezourlo, 41110 Larissa, Greece, Email:

Keywords

Ulcerative colitis • Biologic therapies • Anti-tnf

Introduction

Inflammatory Bowel Disease (IBD), which includes Crohn's Disease (CD) and Ulcerative Colitis (UC), is characterized by chronic inflammation of the gastrointestinal tract. The pathogenesis of IBD involves a complex interplay of genetic, environmental and immunological factors. Traditional treatment options, such as corticosteroids and immunosuppressants, often have limited efficacy and significant side effects. Biologic therapies have emerged as a promising alternative, targeting specific molecules involved in the inflammatory process. This review aims to examine the recent advances in biologic therapies for IBD, focusing on their efficacy in clinical practice and associated safety profiles [1].

Literature Review

Anti-TNF (tumor necrosis factor) agents were the first biologics approved for IBD treatment and include infliximab, adalimumab and certolizumab pegol. These agents work by neutralizing TNF, a pro-inflammatory cytokine involved in IBD pathogenesis. Clinical trials and real-world studies have demonstrated their efficacy in inducing and maintaining remission in both CD and UC. However, long-term use of anti-TNF agents can lead to the development of antibodies against the drug, loss of response and an increased risk of infections and malignancies [2].

Integrin inhibitors, such as vedolizumab and natalizumab, target the interaction between integrins and their ligands, preventing the migration of inflammatory cells into the gut. Vedolizumab, which specifically targets the α4β7 integrin, has shown efficacy in inducing and maintaining remission in UC and CD with a favorable safety profile. Natalizumab, targeting α4 integrin, is effective but associated with a risk of progressive multifocal leukoencephalopathy (PML), limiting its use [3].

Ustekinumab, an IL-12/23 inhibitor, blocks the shared p40 subunit of interleukin-12 and interleukin-23, cytokines involved in the inflammatory cascade. It has demonstrated efficacy in patients with moderate to severe CD and UC who have failed other therapies. The safety profile of ustekinumab is generally favorable, with lower rates of serious infections and malignancies compared to anti-TNF agents [4].

Discussion

Biologic therapies have transformed the treatment landscape of IBD, offering targeted approaches with improved efficacy and safety compared to traditional therapies. Anti-TNF agents have been the cornerstone of biologic treatment, but the emergence of integrin inhibitors and IL-12/23 inhibitors provides additional options for patients, particularly those who do not respond to or cannot tolerate anti-TNF therapy. Despite their benefits, biologics are associated with potential risks, including infections, malignancies and immunogenicity. Regular monitoring and individualized treatment strategies are essential to maximize therapeutic benefits while minimizing adverse effects. Additionally, the high cost of biologics poses a challenge for healthcare systems and patients [5,6].

Conclusion

Advances in biologic therapies have significantly improved the management of IBD, offering effective options for inducing and maintaining remission. Anti-TNF agents, integrin inhibitors and IL-12/23 inhibitors each have unique efficacy and safety profiles, allowing for tailored treatment approaches. While biologics have revolutionized IBD treatment, ongoing research is needed to further enhance their efficacy, minimize risks and develop new therapeutic targets. Optimizing the use of biologics through personalized medicine and careful monitoring will continue to improve outcomes for patients with IBD.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Mukhtar, Kashif, Hasham Nawaz and Shahab Abid. "Functional gastrointestinal disorders and gut-brain axis: What does the future hold?." World J Gastroenterol 25 (2019): 552.

Google Scholar, Crossref, Indexed at

2. Onwuzo, Somtochukwu, Antoine Boustany, Hadi Khaled Abou Zeid and Asif Hitawala, et al. "Prevalence and Risk Factors Associated With Inflammatory Bowel Disease in Patients Using Proton-Pump Inhibitors: A Population-Based Study." Cureus 15 (2023).

Google Scholar, Crossref, Indexed at

3. Lee, Han Hee, Tae-Geun Gweon, Sung-Goo Kang and Sung Hoon Jung, et al. "Assessment of Fatigue and Associated Factors in Patients with Inflammatory Bowel Disease: A Questionnaire-Based Study." J Clin Med 12 (2023): 3116.

Google Scholar, Crossref, Indexed at

4. Bokemeyer, Arne, Joost Buskermolen, Steffi Ketelhut and Phil-Robin Tepasse, et al. "Quantitative phase imaging using digital holographic microscopy to assess the degree of intestinal inflammation in patients with ulcerative colitis." J Clin Med 12 (2023): 4067.

Google Scholar, Crossref, Indexed at

5. Gajendran, Mahesh, Priyadarshini Loganathan, Anthony P. Catinella and Jana G. Hashash. "A comprehensive review and update on Crohn's disease." Disease-a-month 64 (2018): 20-57.

Google Scholar, Crossref, Indexed at

6. Meima-van Praag, Elise Maria, Christianne Johanna Buskens, Roel Hompes and Wilhelmus Adrianus Bemelman. "Surgical management of Crohn’s disease: A state of the art review." Int J Colorectal Dis 36 (2021): 1133-1145.

Google Scholar, Crossref, Indexed at